Ophthalmology Times Newsletter

To view this email as a web page, click here.

Coverage from ASRS 2018 Day 2

Numerous advances in diabetic eye disease, but many questions remain

With all the technological and medical advances for the treatment of diabetic eye diseases, retinal specialists still have an ongoing therapy issue because patients require continual and constant monitoring and maintenance, says Rishi P. Singh, MD.

Targeted therapy may be on horizon for ocular melanoma

A novel light-activated technology may be the first targeted therapy developed for the most common primary cancer of the eye, says Amy C. Schefler, MD.

What makes pneumatic vitreolysis 'highly effective' for VMT?

Calvin Mein, MD, explains why intraocular injection of C3F8 gas alone with limited face-down positioning appears to be a viable alternative for treatment of symptomatic VMT and small stage-2 macular holes.

How AMD patients are treated in the 'real world'

Brolucizumab: Next-generation of anti-VEGF therapy?

What APL-2 means for geographic atrophy

Couldn’t make it to ASRS? Watch the live coverage here!

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.